Cargando…
Real-world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: Evidence from dispensing data
BACKGROUND: Phenylketonuria (PKU) is an inborn metabolic error characterized by a deficiency of the enzyme required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. Pegvaliase (Palynziq®) is an enzyme substitution therapy approved for adults with P...
Autores principales: | Lah, Melissa, Cook, Keziah, Gomes, Dumingu Aparna, Liu, Stephanie, Tabatabaeepour, Nadia, Kirson, Noam, Chen, Er, Lindstrom, Kristin, Whitehall, Kaleigh Bulloch, Van Backle, Joost, Burton, Barbara K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513695/ https://www.ncbi.nlm.nih.gov/pubmed/36176956 http://dx.doi.org/10.1016/j.ymgmr.2022.100918 |
Ejemplares similares
-
Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics()
por: Adams, Darius, et al.
Publicado: (2021) -
Evidence- and consensus-based recommendations for the use of
pegvaliase in adults with phenylketonuria
por: Longo, Nicola, et al.
Publicado: (2018) -
Case-control study about the acceptance of Pegvaliase in Phenylketonuria
por: Krämer, Johannes
Publicado: (2020) -
Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
por: Patrawala, Meera, et al.
Publicado: (2020) -
Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria
por: Zori, Roberto, et al.
Publicado: (2019)